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Hypoxia inducible factors (HIFs) are well characterized to being functionally 
distinct in their transcriptional activity as well as exerting opposing effects on other 
transcription factors, notably c-MYC. While evidence has shown HIF1a inhibits while 
HIF2a promotes MYC activity, such efforts were not done within the context of ccRCC. 
Here we describe our efforts to investigate MYC activity in the presence of HIF2a (H2) 
or HIF1a and HIF2a (H1H2). While we confirmed HIF2a cells show elevated cell cycle 
promoting genes, such results did not correlate to any observable genome-wide 
significant difference in MYC dependent genes. 
 Renal carcinoma is a common and aggressive malignancy whose 
histopathogenesis is incompletely understood and that is largely resistant to cytotoxic 
chemotherapy. We present two mouse models of kidney cancer that recapitulate the 
genomic alterations found in human papillary (pRCC) and clear cell RCC (ccRCC), the 
most common RCC subtypes. MYC activation results in highly penetrant pRCC tumours 
(MYC), while MYC activation, when combined with Vhl and Cdkn2a (Ink4a/Arf) deletion 
(VIM), produce kidney tumours that approximate human ccRCC. RNAseq of the mouse 
tumours demonstrate that MYC tumours resemble Type 2 pRCC, which are known to 
harbour MYC activation. Furthermore, VIM tumours more closely simulate human ccRCC. 
Based on their high penetrance, short latency, and histologic fidelity, these models of 
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CHAPTER 1: INTRODUCTION 
 
Renal cell carcinoma exists as several histological subtypes 
Renal cell carcinoma (RCC) ranks among the ten most common cancers in the 
United States with an estimated 73,820 new cases and 14,770 deaths to occur in 
20191. RCC is a heterogeneous disease with several histological subtypes that possess 
distinct genetic alterations and clinical outcomes.  The major histological subtypes (with 
³ 5% incidence) include clear cell RCC (ccRCC), papillary RCC (pRCC), and 
chromophobe RCC (chRCC)2. The remaining subtypes are very rare, each with £ 1% 
total incidence, and they include MiT family translocation, collecting duct (cdRCC), 
medullary, and clear cell papillary RCC as well tumors considered to be unclassified if 
they do not fit into any the categories listed. 
Clear cell RCC tumors are the most prevalent and malignant subtype of RCC 
and make up approximately 75% of RCC tumors2. These tumors derive their name from 
the ‘clear’ appearance of lipid laden cells—making ccRCC histologically distinct from the 
other subtypes. ccRCC tumors are further characterized by the biallelic loss of the von 
Hippel-Lindau (VHL) tumor suppressor gene, which encodes the protein VHL (pVHL)— 
the substrate recognition component of the E3 ubiquitin ligase that degrades hypoxia-
inducible factors (HIFs). Loss or inactivation of VHL leads to aberrant accumulation of 
HIFs—resulting in uncontrolled activation of HIF target genes that regulate 
angiogenesis, glycolysis, and apoptosis.3 In addition to VHL loss, recent genomic 
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studies have discovered additional significantly mutated genes in ccRCC such as those 
involved in chromatin remodeling: SETD2, BAP1, and PBRM14–6. These genes, 
including VHL, make up the characteristic deletion of chromosome 3p unique to ccRCC. 
Papillary RCC tumors make up approximately 10-15% of RCC tumors and is 
histologically characterized by the arrangement of tumor cells in a papillary 
configuration with fibrovascular cores. pRCC is further subclassified into two subtypes—
pRCC Type 1 and pRCC Type 22. pRCC Type 1 tumors make up the majority of 
papillary RCC tumors (approximately 60-70%) and are associated with activation of the 
mesenchymal-epithelial transition factor (MET)7 proto-oncogene whereas pRCC Type 2 
tumors (making up approximately 30-40% of pRCC tumors) have been shown to be 
associated with activation of MYC, also a proto-oncogene8.  
Chromophobe RCC (ChRCC) makes up approximately 5% of all RCC tumors. 
Although ChRCC is considered quite indolent compared to ccRCC tumors, with greater 
than 90% 10 year cancer-specific survival, aggressive features and metastasis can 
occur. ChRCC is defined by two histologic categories, “classic” and “eosinophilic”. 
Classic ChRCC demonstrate classical pale cytoplasmic features for which the disease 
is named while eosinophilic is defined based on abundant, eosinophilic cytoplasm and 
densely packed mitochondria.9 Furthermore, ChRCC is associated with germline 
mutation of folliculin (FLCN) in the autosomal-dominant cancer predisposition Birt-Hogg 
Dube` (BHD) syndrome10, as well as germline mutation of PTEN in Cowden 
syndrome.11  
New methodologies such as next generation sequencing has made it possible to 
develop a deeper understanding to the underlying genetic alterations responsible for the 
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tumorigenesis of RCC. Such revelations have warranted the need to stratify patients 
accordingly in an attempt to ultimately curate therapies specific to the unique genetic 
alterations each subtype harbors. Researchers and clinicians can better investigate the 
relationship between molecular elements and clinical features as well as therapeutic 
responses to active and new therapies. 
Overview of VHL 
 
pVHL is a component of a complex with ubiquitin ligase activity 
 
While VHL constitutes the most frequent and notable sporadic mutation of 
ccRCC tumors, it was first discovered within the context of VHL disease—a hereditary, 
autosomal-dominant disease associated with various tumor types including ccRCC 
tumors, central nervous system and retinal hemangioblastomas, pheochromocytomas 
and pancreatic neuroendocrine tumors, in addition to pancreatic and renal cysts. VHL 
disease was named by Eugen von Hippel for his description of retinal angiomatosis as 
well as Arvid Lindau for his description of cerebellar and spinal hemangioblastomas—
hence von Hippel Lindau (VHL). Patients with VHL disease possess a single mutated 
allele and tumor development depends upon the spontaneous inactivation or loss of the 
second wild type allele. Early research demonstrated VHL as a tumor suppressor gene 
(TSG) from studies of loss of heterozygosity (LOH) showing that inactivation of both 
VHL alleles is a crucial event in the development of neoplasms in both VHL disease and 
sporadic ccRCC. In addition, biological evidence demonstrated that the re-introduction 
of the wild type VHL protein (pVHL) into a VHL-null ccRCC cell line had no significant 
effect on proliferation in vitro but pVHL did inhibit the ability of cells to form tumors in 
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vivo within nude mice.12 Such evidence suggests that pVHL may rely upon cell-
extracellular matrix interactions that cannot be adequately replicated in vitro. 
 The VHL gene encodes two isoforms of pVHL—a 30kDa form, pVHL30 and a 
19kDa form, pVHL19. pVHL19 lacks the 53 amino acid amino terminal pentameric acid 
repeat domain and is the dominant isoform expressed in many tissues. However, 
functional studies suggest that both isoforms exhibit the same effects in assays12 and 
they both have tumor suppressor activity in vivo13. Early biochemical studies revealed 
that pVHL forms a tertiary complex with transcription elongation factors B and C 
(referred to as elongin B and elongin C). This complex is termed the VCB complex and 
is crucial for pVHL function. Furthermore, pVHL itself is comprised of the tightly coupled 
alpha and beta domains. The alpha domain is in direct contact with elongin C while the 
beta domain serves as the substrate recognition subunit of pVHL. The VCB complex 
nucleates a complex containing the following proteins: cullin 2 (CUL2) and the RING 
finger protein RBX1—forming the VCB-CR complex. Elongin B and C act as adapters 
that link pVHL to heterodimers of CUL2 and RBX1—thereby stabilizing pVHL with 











Figure 1.1 pVHL is part of the E3 ubiquitin ligase  
 
 
In turn, elongins B and C are also stabilized through their interactions with each other 
and pVHL. However, mutations in pVHL that disrupt elongin binding are unstable and 
are readily degraded by the proteasome. Interestingly, mutations in TCEB1 (which 
encodes elongin C) affecting the ability of elongin C to bind to pVHL have been 
described in ccRCC4. Such functional and genomic studies demonstrate that VHL 
mutations relate to the dysfunction of the VCB complex and not just pVHL alone. It was 
noted early on that the VCB-CR complex structurally resembled that of the Skp1-Cdc53-
F box protein (SCF) ubiquitin ligases in yeast. Subsequent work revealed that the VCB-
CR complex also has ubiquitin ligase activity and is capable of targeting proteins for 
proteasomal degradation14–17. 
pVHL-HIF axis 
It was noted early on that VHL disease tumors were highly vascularized and 
overproduced angiogenic polypeptides such as vascular endothelial growth factor 
(VEGF). Early biochemical studies revealed that pVHL may play a critical role in the 
cellular signaling generated by changes in oxygen levels when ccRCC cells lacking wild 
type pVHL were observed to produce high levels of VEGF, glucose transporter 1 
(GLUT1), and platelet-derived growth factor subunit B (PDGFB) mRNAs regardless of 
Cul2







oxygen levels—that is in either normoxic or hypoxic conditions. Reintroduction of wild 
type pVHL inhibited the production of these mRNAs under normoxic conditions. 
Furthermore, Maxwell and colleagues demonstrated the crucial role for pVHL in the 
regulation of hypoxia-inducible factor 1a (HIF1a)18. Subsequent studies over the next 
few years elucidated the details of the pVHL-HIF pathway and the role of the VCB-CR 
complex in targeting HIFs for polyubiquitylation and proteasomal degradation.  
The elucidation of the crystal structure of the VCB complex bound to the carboxy-
terminal oxygen-dependent degradation domain of HIF1a supported evidence17 that 
HIFa (both HIF1a and HIF2a) bind exclusively to the b-domain of pVHL. Such binding is 
dependent upon the hydroxylation of two conserved proline residues within HIF1a 
(P402 and P564) and HIF2a (P405 and P531) by prolyl hydroxylase (PHD) 1 (PHD1), 
PHD2, and PHD3. These hydroxylases require oxygen as a co-substrate (as well as 
iron and 2-oxoglutarate) and are thereby only active under normoxic conditions19–21. 
Prolyl-hydroxylation of HIF1a allows for its recognition and ubiquitylation by the VCB-
CR complex—leading to polyubiquitylated HIFs and subsequent proteasomal 
degradation. During hypoxic conditions (or in the absence of functional pVHL), HIFa 
subunits accumulate, translocate to the nucleus,  and form heterodimers with its HIFb-
subunit. These heterodimers bind to hypoxia-response elements (HREs) throughout the 
genome and activate genes that promote adaption to acute or chronic hypoxia. Of note, 
HIF1a and HIF2a subunits are constitutively transcribed through a series of signaling 
pathways22. However, they are quickly degraded under normoxic conditions and 
generally have a half-life of approximately five minutes23. This oxygen dependent 
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regulation of HIFa subunits is now appreciated as being a fundamental process in how 
cells sense oxygen (Figure 1.2). 
 
Figure 1.2 pVHL-HIFa pathway 
 
 
Hypoxia-inducible factors (HIFs) 
 
Structure of HIF proteins 
HIF transcription factors exist as heterodimers with an oxygen labile a-subunit (of 
which there are three isoforms: HIF1a, HIF2a, and HIF3a) and a stable b-subunit 
(HIF1b; also known as aryl hydrocarbon receptor nuclear translocator (ARNT)). Of note, 
HIF1b derives its name ARNT because it was identified as a heterodimeric partner of 
the aryl hydrocarbon receptor (AhR). AhR is a ligand-activated transcription factor that 
controls the expression of a diverse set of genes24. HIF1b binds to AhR faciliting its 












































Induction of HIF target genes
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because their structures are related to two nuclear proteins found in Drosophila (Per 
and Sim, PAS) which have basic-helix-loop-helix (bHLH) motif26. The bHLH proteins are 
characterized by harboring recognizable domains (b, HLH,  PAS, and TAD) which can 
regulate their own transcription as well as the expression of other family members. The 
bHLH-PAS motifs are generally essential for heterodimer formation between HIFa and 
HIF1b subunits and binding to HRE sequences of target genes. More specifically, the 
base domains (b) have DNA binding properties required for HRE binding while HLH 
motif is where the dimerization with other proteins takes place. The PAS is the only 
domain conserved among all members of this protein family (HIFa, HIF1b, AhR, and 
PAS).  
 The HIFa subunits have two transactivation domains (TAD). They are the NH2-
terminal (N-TAD) and COOH-terminal (C-TAD) domains and they are both responsible 
for the transcriptional activity of the a-subunits27. C-TAD interacts with the co-activators 
CREB binding protein and its paralogue p300 (CBP/p300) to modulate gene expression 
of HIFa28. N-TAD is known for providing a-subunits stability and protection from 
degradation29. Furthermore, a-subunits are distinct from their b-dimeric partner in that 
they possess an oxygen-dependent degradation domain (ODDD) that overlaps the N-
TAD in their structures. The ODDD is crucial for mediating oxygen dependent stability in 
that it contains specific proline residues that are hydroxylated by PHDs in normoxia19. It 
also serves as the region that is recognized by pVHL’s substrate recognition, b-







Figure 1.3 Regulatory domains of HIFa and HIF1b subunits 
 
 
There are three HIFa subunits known to date: HIF1a, HIF2a, and the less well 
characterized HIF3a27,31. HIF1a and HIF2a share the most amino acid sequence 
similarity with HIF2a having 48% of sequence similarity to HIF1a. While they are similar 
in structure and sequence, they are expressed in different tissue patterns. HIF1a is 
expressed ubiquitously while HIF2a expression is limited to the kidney, heart, 
endothelium, small intestine, and lungs31,32. Although less is known about HIF3a, 
researchers have found that HIF3a gives rise to multiple HIF3a variants 22. These 
variants are quite varied in that they are expressed in different tissue patterns, at 
different developmental stages, and are even differentially regulated by hypoxia and 
other factors. Evidence suggests that some variants act as dominant-negative 

















HIF1a and HIF2a (collectively referred to as HIFs) are stabilized in hypoxic 
conditions or when VHL is inactivated—as is the in case in ccRCC. However, extensive 
evidence has revealed that HIF1a and HIF2a are not fully redundant in function or 
target gene expression.  
HIF1a and HIF2a transactivation domains 
Early mouse studies indicated that HIF1a and HIF2a possess some unique 
characteristics. Targeted deletions of each isoform resulted in embryonic lethality, 
however the phenotypes were different. HIF1a-/- embryos were observed to have 
severe blood vessel defects and died by E1134. HIF2a-/- embryos were observed to 
have severe blood vessel defects in addition to bradycardia and abnormal lung 
maturation with death occurring by E13.535. 
 While HIF1a and HIF2a do harbor the same regulatory domains, variability 
between them is observed mostly within the N-TAD. Specifically, evidence has shown 
that it is the N-TAD that confers target gene specificity of HIF1a and HIF2a36. The C-
TAD is homologous between both isoforms and promotes the expression of their 
common target genes36. As such, HIF1a preferentially activates genes involved in 
glycolysis such as phosphoglycerate kinase (PGK) and lactate dehydrogenase 
(LDH)37,38. HIF2a activates genes involved in tumor growth, stem cell pluripotency, and 
cell cycle progression such as Oct-4 and Cyclin D139,40. As previously described, the 
hydroxylation of specific proline residues contributes to a mechanism of HIFa stability. 
However, another mechanism of HIFa regulation depends upon the hydroxylation of a 
conserved asparagine residue (N803 in HIF1a and N851 in HIF2a) located in the C-
TAD by the asparaginyl hydroxylase, factor inhibiting HIF (FIH-1). Like the PHDs, FIH-1 
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requires iron and a-ketoglutarate41. FIH-1 prevents the interaction between the C-TAD 
and the essential co-activators CBP/p300—rendering the C-TAD nonfunctional and 
directly inhibiting the transcription of C-TAD dependent genes41. Subsequent research 
has suggested that HIF2a is more resistant to FIH-1 inhibition than HIF1a. This may be 
due to the differences of the surrounding amino acids within the respective C-TAD42. 
HIF independent functions of pVHL 
 
pVHL’s role in apoptosis 
While pVHL was first characterized through its interaction with HIFa subunits, 
growing evidence has emerged suggesting that pVHL plays a role in regulating cellular 
processes independent of HIFs. ccRCC tumors are known for their resistance to 
conventional cytotoxic chemotherapies and such efficacy of chemotherapy is closely 
associated to p53-mediated apoptosis43. However, most ccRCC tumors do not harbor 
p53 mutations or loss suggesting either activation of alternative anti-apoptotic pathways 
or functional modulation of p53 activity43. Previous studies have shown that HIF can 
directly bind to and modulate p53 activity44–46. Additionally, pVHL is able to stabilize p53 
in a HIF-independent manner by suppressing MDM2-medidated ubiquitination and 
nuclear export resulting in increased transcriptional activity47.  
Genetically engineered mouse models (GEMMs) of RCC 
 
Inactivation of Vhl in murine kidneys does not recapitulate human RCC 
Accumulating knowledge on the underlying biology of RCC has led to the 
development of targeted therapy blocking the von Hippel Lindau (VHL)-hypoxia 
inducible factor (HIF) pathway and its gene products or the mTOR pathway48—leading 
to improved clinical outcomes. However, it remains that a subset of patients are 
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intrinsically refractory to such targeted therapies and most patients exhibit tumor 
regression only during the first few months of treatment. Drug resistance typically 
occurs after a median of 6 to 15 months of treatment, leading to cancer progression and 
eventual death49. A recent resurgence of immunotherapy has shown great promise for 
patients with advanced RCC who are refractory to other treatments50. The role of these 
emerging treatments for the management of metastatic RCC still needs to be 
established with ongoing trials along with the opportunities to perform precision based 
medicine. Such efforts call for the generation of preclinical animal models. Genetically 
engineered mouse models (GEMMs) serve as powerful tools to explore the 
tumorigenesis of a wide variety of cancers as well as indispensable preclinical models 
for drug testing. While ccRCC is among one of the few cancers known to evolve from a 
specific genetic mutation, mouse models that recapitulate its characteristic molecular 
and cellular features have not generated the expected outcome. Fortunately, 
extraordinary efforts have been made within the past few years to take on the challenge 
of developing mouse models of ccRCC that are faithful to the human disease.  
As described above, VHL inactivation has been shown to occur in approximately 
92% of sporadic ccRCCs4. The role of VHL as a tumor suppressor in cancer has been 
established by the fact that reintroducing wild type VHL into VHL null RCC cell lines 
disrupts their capacity to form tumors in immune-comprised mice12,51. However, early 
efforts have revealed that inactivation of VHL within kidney cells do not transform cells 
or produce RCC within mice. Homozygous germline deletion of Vhl in mice led to 
embryonic lethality52. Furthermore, a mosaic deletion53 or heterozygous deletion of 
Vhl54,55 does not predispose mice to RCC—in contrast to what occurs in humans56. 
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Subsequent efforts have focused on generating models that utilize the Cre-Lox system 
to control spatiotemporal mutations of genes shown to be involved in the tumorigenesis 
of RCC.  
The proximal tubular epithelial cells are generally believed to be the cell of origin 
of RCC and have been the first targets for conditionally targeting cells in the kidney. 
Specifically, Rankin and colleagues developed the first conditional knockout mouse 
model using the phosphoenolpyruvate carboxykinase (PEPCK)-Cre system to delete 
Vhl in renal proximal tubule cells. While they did observe cellular proliferation, lipid 
accumulation, and macroscopic renal cysts in 18% of mice over a year old, no RCC 
development was observed before mice reached 25 months57. Because accumulated 
evidence has indicated that ccRCC can at least partially originate from non-proximal 
tubules, such as the distal convoluted tubules and collecting ducts58, some researchers 
have attempted to target non-proximal tubule cells of the kidney.  
Frew and colleagues generated a conditional Vhl knockout mouse within the 
distal tubules and collecting ducts using the Ksp1.3-Cre system (which is also 
expressed in proximal tubules) and found no abnormalities other than hydronephrosis59. 
Another mouse model was generated by using Hoxb7-Cre to inactivate Vhl in the 
collecting ducts and a subset of distal tubules within the kidney. Mice exhibited 
hyperplasia, presence of clear cells and cysts, and disrupted structures—but no 
development of ccRCC60. Such efforts have revealed that VHL loss alone is insufficient 
for tumorigenesis within the mouse kidney.  It is generally accepted that additional 
mutations in other tumor suppressors or oncogenes are required to initiate 
tumorigenesis. In accordance with this hypothesis, researchers have combined deletion 
 14 
of VHL with the deletion or activation of other tumor suppressors and oncogenes, 
respectively, in efforts to promote ccRCC development. 
Inactivation of Vhl and PTEN 
The inability to produce ccRCC in mice by only inactivating Vhl supports the idea 
of combining additional genetic mutations to recapitulate the tumorigenesis of ccRCC. 
Large-scale genomic studies have revealed recurrent altered genes and pathways other 
than VHL inactivation. These genes and pathways may function cooperatively with the 
VHL pathway (as described above) and serve as good candidates to be investigated in 
ccRCC GEM models.  
 The involvement of phosphatase and tensin homolog (PTEN)  and the PI3K/AKT 
pathway within ccRCC was established in early research by Velickovic and colleagues61 
and has been reconfirmed by recent genomic studies that approximately one-fifth of 
patients harbor mutations in genes involved in this pathway. PTEN is one of the most 
frequently disturbed tumor suppressor genes in sporadic cancers and negatively 
regulates the PI3K/AKT pathway. The PI3K/AKT pathway plays a crucial role in the 
cellular metabolism, proliferation, and survival62. Based upon these facts, Frew and 
colleagues generated a conditional co-deletion of Vhl and Pten in mouse kidney 
epithelial cells using the Ksp1.3-Cre system59. All of these mice developed cysts lined 
with reduced cilia and clear cell epithelial cells within only two months of age. No overt 
tumors were observed due to the euthanasia of mice within 3-6 months to avoid renal 
failure. However, such a combination elicited cyst formation with a short latency; 
encouraging further investigation of other combinatorial genetic alterations. 
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Inactivation of Vhl and p53 
 The TP53 gene is a crucial and well known tumor suppressor—encoding its 
product, p53. p53 has been well characterized and serves to protect cells from DNA 
damage and transformation. TP53 is regarded to be quintessential in tumorigenesis due 
to its frequent alteration in diverse and approximately half of all cancer types63,64. Unlike 
mutations of PTEN that typically abolish its tumor-suppressing function, mutations of 
TP53 often confer neomorphic functions that are oncogenic in nature65. Although TP53 
mutations occur only in a small subset of ccRCC patients (2.08%)5, p53 pathway-
regulated genes, such as MDM2, CHEK2, ATM, and CDKN2A, are functionally mutated 
in approximately one-fourth of patients4,6. Albers and colleagues set out to investigate 
the role of TP53 mutations in the tumorigenesis and progression of RCC. They 
generated a conditional co-inactivation of Vhl and Trp53 in the kidney epithelium of mice 
using Ksp1.3-Cre. Researchers observed tumorigenesis within the urinary tract as well 
as renal cysts in three-fourths of mice after one year. In addition, neoplasms were 
observed containing cells that showed altered proliferation as well as cytoplasmic 
clearing but no ccRCC tumors. Furthermore, molecular investigation revealed elevated 
expression of MYC and target of rapamycin complex 1 (mTOR)—demonstrating that 
inactivation of Vhl and Trp53 induces the development of renal cysts and ultimately 
progression to dysplastic and malignant lesions66.  
Inactivation of Vhl and Kif3a 
 The primary cilium is an organelle that is microtubule-based and found in several 
cell types. It mostly functions as a luminal flow sensor and is involved in regulating 
tubular cell proliferation within the kidney67. As previously stated, pVHL mediates 
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numerous biological activities including the stabilization of the microtubule network68 
and is important for the regulation of the primary cilium69. The importance of the primary 
cilium in renal tumorigenesis and cytogenesis in conjunction with the fact that a subset 
of ccRCC tumors develop in a cyst-dependent manner led researchers in interrogate 
the effects of Vhl inactivation coupled with the specific ablation of primary cilia in the 
kidney. Lehmann and colleagues conditionally deleted the kinesin family member 3A 
(Kif3a) gene, which encodes a protein subunit of the kinesin-II microtubule motor 
complex that is essential for cilia formation, along with Vhl. Both mutations were carried 
out using the Ksp1.3-Cre system. The combined loss of Vhl and Kif3a resulted in the 
formation of renal cysts with a shortened latency of cyst initiation as well as increased 
total cystic burden and frequency in all mice70.  
Inactivation of Vhl, Trp53, and Rb1 
 Noteworthy efforts by Harlander and colleagues demonstrated success in 
developing a mouse model of ccRCC by combining deletions of Vhl, Trp53, and Rb1 in 
kidney epithelial cells (Ksp-Cre system)71. The majority of mice (more than 80%) 
developed an average of five tumors per mouse within 25-61 weeks of somatic 
mutation. Pathological examination revealed classic clear cell tumor cells, necrosis, and 
intratumoral hemorrhage. Immunohistochemical staining exhibited nuclear accumulation 
of HIF1a and HIF2a—predictive of Vhl loss. Additionally, strong immunoactivity of 
carbonic anhydrase IX (CAIX), a marker known to be highly expressed in RCC tumors 
and thought to play a role in cellular proliferation in response to hypoxic conditions was 
detected72 as well as tissue markers indicative of proximal tubule cell of origin. 
mTORC1 activation was confirmed and RNA-seq analysis showed strong correlation in 
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between the global transcriptional profiles of the triple-mutant mouse tumors and human 
ccRCC tumors. This mouse model has been tested in preclinical therapeutic studies, 
with individual ccRCC mice showing varied sensitivity to sunitinib and everolimus 
treatment. This suggests that this model would be useful to interrogate mechanisms of 
drug resistance and to identify potential therapeutic biomarkers. Although the pathways 
regulated by these genes are frequently altered in ccRCC, albeit through different 
mechanisms, the inactivation of Vhl, Trp53, and Rb1 is not common in human ccRCC 
and may reflect only a small subset of human ccRCCs.  
Inactivation of Vhl and Bap1 
 As previously described, next-generation sequencing has led to the identification 
of additional recurrent mutations found to reside near VHL, on chromosome 3p. These 
mutations occur in chromatin remodeling genes and include SETD273, BAP174, and 
PBRM175. Such efforts have offered researchers rationale to assume that these genetic 
alterations may function cooperatively with VHL inactivation to develop ccRCC.  
 BRCA-1 associated protein 1 (BAP1) is a nuclear-localized histone 
deubiquitinase that binds to the BRCA1 RING finger domain and functions are a tumor 
suppressor in various cancers76,77. Approximately 14% of ccRCC harbor sporadic loss 
of BAP1 and is associated with a high-grade subset of ccRCC tumors74. Wang and 
colleagues set out to investigate the effects of combined inactivation of Vhl and Bap1 
using the Six2-Cre system78. SIX Homeobox-2 (Six2) is expressed specifically within 
nephron progenitor cells of the kidney. Mice harboring loss of Bap1 alone were 
moribund and died before 1 month of age. Mice deficient in Vhl and only one allele of 
Bap1 were initially morphologically normal but displayed increasingly extensive 
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abnormalities in histology starting at only 1 month of age. Perhaps most notable was the 
observation that lesions spanned from premalignant cysts to cystic and solid RCC 
tumors were identified—recapitulating such manifestations seen in patients with VHL 
syndrome. Molecular examination revealed positive CAIX staining as well as elevated 
staining for phosphor-S6, a downstream target of mTORC1 activation. Such results 
indicate that this mouse model was able to reproduce some features of human ccRCC. 
It should be noted that the loss of chromosome 3p in humans can simultaneously cause 
both VHL and BAP1 deletion, but this would not occur in mice due to the fact that Vhl 
and Bap1 reside on different chromosomes. 
 Based upon the mouse model of Vhl loss and a heterozygous loss of Bap1, the 
same group attempted a double deletion using different Cre drivers. While the Six2-Cre 
model led to mice dying shortly after birth and small kidney tumors; Sglt2-Cre and Villin-
Cre systems (both are expressed within the proximal convoluted tubules) failed to 
induce tumors. The authors found success utilizing the paired box 8 (PAX8)-Cre 
system79. PAX8 encodes a transcription factor that plays a critical role in kidney 
development and is expressed in the mesonephros, metanephros, nephric duct, and 
ureteric bud—the complete tubular system80. These mice, harboring homozygous 
deletions of Vhl and Bap1, lived to approximately three months of age. However, these 
mice developed small RCC tumors and cystic lesions in the kidneys—with similar 
morphological features of Six2-Cre derived tumors. Authors also generated mice 
deficient in Vhl and one allele of Bap1 using PAX8-Cre system. In contrast to the double 
deletion, these mice had a median survival of 14.5 months; displaying cystic lesions at 
10 months and tumors at 11 months of age. Both PAX8-Cre models showed elevated 
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expression of HIF target genes and increased mTORC1 activation—consistent with 
clinical features of human ccRCC with BAP1 deficiency. Of note, this study proposed 
evidence that the Bowman’s capsule, rather than the proximal tubule, to be the cell of 
origin of ccRCC.  
Inactivation of Vhl and Pbrm1 
 Genomic sequencing has identified PBRM1 to be the second most frequently 
mutated gene in sporadic ccRCC75. PBRM1’s product is a subunit of the SWI/SNF 
chromatin remodeling complex, and is located on chromosome 3p near VHL. Several 
groups have generated mouse models with PBRM1 deletion in attempts to recapitulate 
human ccRCC. Nargund and colleagues investigated the role of Pbrm1 in the 
tumorigenesis of ccRCC by inactivating both Vhl and Pbrm1 using a Ksp-Cre system in 
induce the deletion of both genes at the embryonic stage81. These mice developed 
preneoplastic polycystic kidney disease at 6-9 months of age with a 30% incidence. In 
addition, histologic examination revealed a 50% tumor incidence at 10 months of age. 
Such tumors showed key features of human ccRCC, including clear cytoplasm, positive 
CAIX staining, and hyperactive mTORC1 signaling. In addition the origin of these 
tumors from proximal tubules and gene expression profile suggests the tumors 
resemble ccRCC rather than other types of RCC.  
 Another group developed a mouse model of RCC using Pax8-Cre deletion of Vhl 
and Pbrm1. Their results showed the majority of mice (85%) presented with bilateral, 
multiple, large, and homogenous tumors at only 9 months of age with 100% of mice 
presenting with tumors by 13 months of age. Tumor size increased with age until almost 
encompassing the whole kidney at 16 months of age79.  
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 While both studies confirmed the tumor suppressive role of PBRM1 and that 
combinatorial deletion of VHL and PBRM1 predisposes mice to ccRCC—the two 
models have contradictory conclusions in terms of mTORC1 status. The model utilizing 
Ksp-Cre showed elevation of mTORC1 while the Pax8-Cre system showed hypoactive 
mTORC1 expression. Such differences may be due to differences in cell of origin of 
ccRCC.  
 Gu and colleagues studied the simultaneous deletion of Vhl/Pbrm1 and Vhl/Bap1 
and discovered that Bap1 and Pbrm1 play an important role in determining tumor 
grade79 —compatible with findings that mutations of BAP1 and PBRM1 are associated 
with tumor grade, aggressiveness, and patient survival in human ccRCC74,82. This group 
further investigated the pathway underlying the tumor grade differences in BAP1 and 
PBRM1 deficient ccRCC. BAP1 deficient tumors harbor activated mTORC1 (such 
activation of mTORC1 not observed in PBRM1 null cRCC) which leads to a high grade 
and aggressive tumor. Furthermore, the loss of one copy of TSC1 in PBRM1 null 
ccRCC to drive activation of mTORC1 resulted in the low grade tumors to become high 
grade. Such distinctions are critical for clinical practice.  
 While the above mentioned GEM models of ccRCC are not exhaustive, they 
represent significant findings and efforts within the field of RCC. Some ccRCC models 
can mimic most of the genetic aberrations found in human ccRCC—making them 
valuable tools to define the casual role of genetic events in ccRCC. Most of these 
models reproduce precursor lesions or a few of the important phenotypes of ccRCC—
signifying the difficulty in successfully developing an autochthonous ccRCC model. 
Such difficulty goes to the fact that outside of VHL inactivation, there has not been an 
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established set of genes that are solely responsible for developing ccRCC within mice. 
However, some of these models (including the VIM GEM model generated by our group 
discussed in Chapter 3) were able to fully reproduce bona fide ccRCC in adult mice. 
Such strides in the generation of these indispensable models provide a means to 
investigate the biological mechanisms underlying tumor progression as well as the 
heterogeneity among patients of a given therapeutic. 
c-MYC: master regulator 
 
Regulatory domains of MYC 
 
c-MYC (MYC henceforth) encodes the MYC transcription factor and plays 
essential roles in cellular proliferation, growth, differentiation, and apoptosis. The Myc 
protein is comprised of several domains that play crucial roles in MYC activity and 
stability. These domains are as follows: an N-terminal transactivation domain (TAD) 
required for transcriptional activation, a central region, and a C-terminal domain (CTD) 
critical for DNA binding and protein interactions. Myc has four conserved regions known 
as Myc boxes (MB) that are essential various functions. The TAD, which is responsible 
for the assembly of transcriptional machinery, contains MBI and MBII. MBI contributes 
to gene activation and protein degradation, while MBII that is critical for most of Myc’s 
functions. The central region contains MBIII and MBIV. MBIII has been implicated in 
transcriptional repression, apoptosis, and transformation while MBIV modulates DNA 
binding and shares some functions of MBIII such as apoptosis and transformation. The 
CTD is comprised of a basic region required for binding to E boxes (CACGTG) and a 
helix-loop-helix leucine zipper (HLHZip) domain that is necessary for dimerization with 
one of its binding partners—Max83. 
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Regulation of MYC as an oncogene 
MYC was first discovered as a homolog of the retroviral v-Myc oncogene in avian 
tumors84. Soon after, a role for MYC in driving human cancer was first identified in B-cell 
Burkitt’s lymphoma, where MYC was found to be deregulated due to its chromosomal 
translocation into the immunoglobulin heavy chain locus85,86. MYC’s transforming ability 
(in cooperation with activated RAS) was first demonstrated within primary rat embryo 
fibroblasts87 and has since been shown to be overexpressed in over 50% of all human 
tumors—supporting the notion that MYC is a human oncogene.  
 Due to its oncogenic potential, MYC is tightly regulated in noncancerous cells at 
transcriptional and post-transcriptional levels via miRNAs and by translation of its own 
mRNA88–90. Post-translationally, MYC protein half-life and transcriptional activity are 
regulated by kinases, ubiquitin ligases, acetyltransferases, and other interacting 
proteins83,88–92. In support of this, evidence has demonstrated that oncogenic KRAS and 
ERK can upregulate MYC, in part, through enhanced protein stability83,93–95. 
Additionally, studies have shown that long noncoding RNAs (lncRNAs) control MYC 
protein stability and activity by altering post-translational modifications92,96. Many growth 
promoting signaling pathways, such as NOTCH and EGFR, converge on MYC—
underscoring the centrality of MYC to cell growth regulation97–103. In stark contrast to 
MYC’s activity within normal cells, MYC amplifications within cancers that increase copy 
number, translocations that pair MYC with highly active enhancers, or viral insertion 
events within the MYC locus abolish MYC’s dependence on growth factor signaling104. 
Changes in the activity of MYC’s enhancers can perturb MYC expression from its 
normally required stimuli, affecting cancer risk and progression. For instance, NOTCH-
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dependent enhancers of MYC appear to be intimately involved in the activation of MYC 
in human T-cell lymphoma105,106. Other enhancers show single-nucleotide 
polymorphisms (SNPs) that affect transcriptional activator TCF-7 binding and 
predispose patients to colon and prostate cancers 107–109.  
Gain of MYC occurs in a subset of ccRCC patients  
Deregulation of MYC expression in cancers is inherently different from regulated 
MYC expression in normal cells. Aberrant expression of MYC is shown to induce a 
transcriptional response network different from the response triggered by endogenous 
normal MYC. Loss of function analysis of MYC reveals its crucial role in the growth of T 
lymphocytes, keratinocytes, and intestinal crypts110–112. Further proof as to the 
difference of MYC’s transcriptional program between cancerous and normal cells is the 
expression of cyclin-dependent kinase inhibitors are generally elevated while 
expression of cyclin-dependent kinases are repressed in resting, or normal, cells.   
Researchers have demonstrated there are a subset of ccRCC tumors that harbor a gain 
of chromosome 8q (where MYC resides). Additional studies have shown ccRCC tumors 
with a gain of 8q24 consistently overexpressed c-MYC. Furthermore, amplification of 
this locus was associated with decreased DSS (disease-specific survival) as well as an 





 The INK4a/ARF locus (also known as CDKN2A on chromosome 9p21) encodes 
two structurally and functionally distinct tumor suppressors: p16Ink4a and p19ARF. These 
proteins have different first exons that are spliced to a common second and third exon. 
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While exons 2 and 3 are shared between p16 and p19, the proteins are encoded in 
alternative reading frames—resulting in no amino acid homology between the two 
proteins (Figure 1.4). 
 
Figure 1.4 INK4a/ARF locus encodes TSGs that regulate cell cycle 
 
 
Cell cycle arrest by p16Ink4a and ARF 
Perhaps the most well studied function shared by inhibitors of Cdk4 (Ink4a) and 
alternate reading frame (Arf) is their ability to cause cell cycle arrest. The tumor 
suppressor proteins Ink4a and Arf function in distinct pathways. Ink4a regulates the 
retinoblastoma (Rb) pathway while Arf regulates the p53 pathway. Upon the induction of 
D-type cyclins by extracellular growth factors, they associate and bind with cyclin-
dependent kinases 4 and 6 (Cdk4 and Cdk6). This cyclin-Cdk complex is responsible 
for phosphorylating, and thereby inactivating, the retinoblastoma protein (pRb). 
Inactivation of pRb results in the activation of E2F-dependent transcription of genes 









which maintains the phosphorylation of pRb in conjunction with Cdk2. Ink4a exerts its 
ability to halt cell cycle progression by binding directly to Cdk4 and Cdk6114, disrupting 
them from associating the D type cyclins. This results in the pRb being in a ‘hypo-
phosphorylated’ state and therefore in an active state—leading the inactivation of E2F-
dependent genes. In addition to inhibiting Cdk4/6, excess Ink4a can inhibit Cdk2 
(thereby disrupting the cyclin E-Cdk2 complex) by causing the redistribution of the p21 
family of Cdk inhibitors from cyclin D-Cdk complexes to cyclin E-containing complexes. 
The net result is an arrest in the G1 phase (Figure 1.4). 
Murine double minute 2 (Mdm2) is well known for being a critical modulator of 
p53 activity by directly promoting p53’s proteasomal degradation114. Interestingly, Mdm2 
is activated by p53—setting up a feedback loop through which p53 function is tightly 
controlled. Arf’s ability to cause cell cycle arrest is due to its binding to Mdm2 and 
inhibiting its E3 ubiquitin ligase activity—resulting the stabilization of p53 and activation 
of its target genes (Figure 1.4). These target genes include p21, which presumably 
underlies Arf’s ability to cause cell cycle arrest. However, several groups have shown 
evidence that there may be other possible mechanisms at play that allow Arf to cause 
cell cycle arrest. It has been shown that Arf has the capacity to arrest mouse embryonic 
fibroblasts (MEFs) that lack p21115 or both p53 and Mdm2116.  
Loss of Ink4a/Arf is occurs in a subset of ccRCC patients 
Ink4a/Arf is deleted in a wide variety of tumors such as bladder cancer, prostate 
cancer, glioblastoma, melanoma, non-small cell lung cancer, and a subset of ccRCC 
tumors. Studies of mice with deletions for Arf or Ink4a have revealed that they become 
more prone to spontaneous cancers than the wild type littermates. However, it would 
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appear that mice lacking both Ink4a and Arf are significantly more tumor prone than the 
single knockout mice117,118. Similarly, germline mutations in Ink4a/Arf in humans are 
associated with familial predisposition to melanoma and certain other cancers.  
 Most studies investigating 9p deletion in primary renal tumors found LOH of 9p21 
locus to the most commonly reported copy number variation (CNV)119,120. In a study by 
El-Mokadem and colleagues, they found that 91% (32 out of 35) of the 9p deletions 
were due to LOH or monosomy. Only three tumors showed deletion of both copies. 
Researchers show that chromosome 9p (where Ink4a/Arf resides) deletion within a 
subset of ccRCC tumors is associated with decreased disease specific survival (DSS) 
and recurrence free survival (RFS)121. Additionally, previous research showed that 
aberrations leading to low expression of Ink4a and p14ARF are associated with 




CHAPTER 2: INVESTIGATING HIF-MYC INTERACTIONS WITHIN CLEAR CELL 
RENAL CELL CARCINOMA 
 
Introduction 
As previously described, HIF1a and HIF2a exhibit unique characteristics within 
RCC. Studies have shown that HIF2a promotes tumor growth in RCC xenograft 
models124–126 whereas overexpression of stable HIF1a inhibits tumor growth126,127. In 
addition, cell cycle arrest can occur during hypoxia through HIF1a-dependent increase 
in cyclin-dependent kinase inhibitor (CKI) p21 and p27128–130. While p21 and p27 are not 
direct HIF1a target genes, their expression is due to HIF1a’s ability to antagonize MYC 
activity by altering MYC’s interaction with Sp1 (one of MYC’s cofactors)—and 
subsequently relieving transcriptional repression at p21 and p27’s promoters131–133. 
Conversely, work from Gordan and colleagues demonstrated that HIF2a has the ability 
to enhance MYC activity by stabilizing MYC’s interaction with Max (another cofactor of 
MYC)—resulting in the activation of MYC target genes, Cyclin D2 and E2F1, involved in 
cell cycle progression134. Such work by Gordan and colleagues were conducted in cell 
lines that expressed either HIF1a (HCT116 cells, colon carcinoma cell line) or HIF2a 
(WT8 cells, 786-O RCC cells expressing pVHL). Research from the same group 
classified 57 independent sporadic ccRCC tumors based upon HIFa expression and 
VHL status. Such efforts revealed that tumors sorted into one of three categories: VHL 
wild type, both HIF1a and HIF2a expression, and HIF2a expression detected 
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exclusively. They found no tumors that only expressed HIF1a—suggesting that HIF2a 
may play a crucial role in the tumorigenesis of pVHL deficient ccRCC135.  
Such findings led us to question how MYC’s transcriptional activity may be 
altered in ccRCC. It was important to utilize a system that reflected the observed HIFa 
status of ccRCC tumors (HIF1a and HIF2a versus HIF2a only) in order to appropriately 
discern MYC activity. In addition, only a few MYC target genes (p21, p27, Cyclin D2, 
and E2F1) were analyzed in experiments delineating MYC activity in the presence of 
either HIF1a or HIF2a. We set out to assess MYC transcriptional activity not only within 
the context ccRCC HIFa status, but also on a genome-wide scale. 
Generating the appropriate ccRCC cell line 
c-MYC transcriptional activity is differentially regulated in the presence of HIF1 or 
HIF2134. We set out to determine whether c-MYC’s transcriptional activity is altered 
within the context of ccRCC. That is, in the presence of HIF2 only or HIF1 and HIF2 
combined. In order to interrogate this question, we generated a RCC4 cell line with the 
following alterations: 1) doxycycline inducible expression of c-MYC as a means to 
control MYC expression and 2) has a loss of HIF1—thereby generating cells that 
express both HIF1 and HIF2 (referred to as H1H2) and HIF2 only (referred to as H2) 
(Figure 2.1a). RCC4s did not show any detectable levels of endogenous MYC at the 
protein level. The RCC4 cell line harbors the characteristic mutant VHL and is widely 
used as a representative ccRCC cell line136. This cell line also expresses both HIF1 and 
HIF2—making it a suitable cell line for our studies. Immunoblot analysis and normalized 
gene expression data confirmed the induction of MYC with doxycycline as well as 
knockdown of HIF1 (Figure 2.1b, Figure 2.3a,b). 
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Figure 2.1. Generation of H1H2 vs H2 cells with inducible MYC expression 
 
(A) Schematic of how RCC4 cell line was generated to yield the respective genetic 
groups for subsequent analysis. (B) Immunoblot from RCC4 cell lines shows c-MYC 
expression is doxycycline dependent. Additionally, knockdown of HIF1 was achieved 
using short hairpin against HIF1 
 
H2 cells display evidence of enhanced cell cycle progression—but no significant 
global differences  
In order to determine whether MYC induction resulted in the activation of genes 
associated in the canonical MYC pathway, we employed the use of a canonical c-MYC 
gene signature list, PID_MYC_PATHWAY. While there was a significant difference 
between cells with induced MYC expression (+MYC) and those without MYC induction 
(-MYC), there was no significant difference between H1H2 versus H2 cells with MYC 
induction. (Figure 2.2) This suggests that while the induction of MYC does yield 
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Figure 2.2. Activation of MYC yields upregulation of canonical MYC pathway genes 
 
 
We hypothesized that H2 +MYC cells would show increased expression of genes 
involved in cell cycle progression compared to H1H2 +MYC cells. To investigate this, 
we analyzed the expression data of the MYC target genes assessed by Gordan et 
al134,135. The c-MYC activated target gene E2F1 was significantly higher in H2 
expressing cells as compared to H1H2 cells. c-MYC repressed target gene, p21, was 
significantly reduced in H2 cells—confirming the observation that H2 cells promote cell 




































































Figure 2.3 H2 cells exhibit increased cell cycle progression 
 
(A) Normalized gene expression profiles of HIF1, (B) c-MYC, (C) p21, and (D) E2F1. 
*P<0.05; **P<0.01, ***P<0.001. P values obtained from Tukey’s test. 
 
In addition, H2 cells exhibit elevated levels of genes involved in the G1/S cell cycle 
phase—further supporting evidence that HIF2a expressing cells are more proliferative 
than H1H2 cells (Figure 2.4). 
Figure 2.4 HIF2 cells exhibit elevated levels of genes involved in G1/S phase 
 
We next set out to determine whether there were significant MYC dependent 
gene expression differences between H1H2 and H2 cells on a genome-wide scale. As 











































































































































































































repressed by MYC in H1H2 or H2 cells. MYC expression (+MYC/-MYC) between H1H2 
and H2 cells revealed surprisingly very little genes that were significantly different 
between the two groups. This was evidenced by genes that were significantly altered in 
H2 (blue) or H1H2 (green) clustering below the 2-fold threshold. Additionally, the 
majority of genes that were significantly altered appeared in both groups (red)—
suggesting that there is no difference in MYC’s transcriptional activity between H1H2 
and H2 cells.  
 




Our group set out to determine whether MYC’s transcriptional activity would be 
significantly altered in VHL deficient ccRCC cell lines expressing either HIF2a (H2) or 



















































































































































































































































was important due to the fact that no ccRCC tumors only express HIF1a135. We also 
wanted to build upon the current knowledge that MYC activity is altered in the presence 
of HIF1a or HIF2a alone by interrogating this question on a genome-wide scale. I 
initially hypothesized that H2 cells would display a significantly distinct MYC 
transcriptional profile compared to H1H2 cells, based upon evidence that H2 ccRCC 
tumors showed evidence of elevated MYC activity compared to H1H2 ccRCC tumors. 
Our generated cell lines partially supported such evidence with the expression of a 
couple MYC target genes (p21 and E2F1). Gene expression data only showed cell 
cycle genes to be the only gene set significantly altered between H1H2 and H2 cells. 
Specifically, genes involved in the G1 to S phase transition.  
 This was, admittedly, a surprising and confounding result. H2 cells showed 
significantly elevated levels of E2F1 while H1H2 cells showed significantly elevated 
levels of p21 (Figure 2.3). This was promising seeing as that Gordan and colleagues 
also observed increased E2F1 in cells only expressing HIF2a134 as well as HIF2a 
expressing ccRCC tumors135. However, subsequent gene set analysis revealed no 
global gene expression differences between H1H2 and H2 cells.  
 It is possible that our findings may be different given that we did not assess MYC 
activity in the context of HIF1a or HIF2a alone. Previous efforts were done in a colon 
carcinoma cell line (HCT116) and a pVHL restored RCC cell line (WT8). Furthermore, 
we did not account for endogenous levels of MYC due to the absence of any detectable 
expression at the protein level within RCC4. Additionally, we controlled for MYC 
expression by generating a doxycycline inducible system to drive exogenous expression 
of MYC. It is quite possible that our system represents an over-driven model of MYC 
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and such expression overwhelms any effect HIFs may be exerting within these cells—
thereby masking any MYC dependent changes between H1H2 and H2 cells.  
 As such, follow up analysis would need to be performed to determine whether 





 RCC4 cells were cultured in 1XDMEM, 10% FBS, 1% PS containing 2 ug ml-1 
doxycycline. In vitro doxycycline was dissolved in DMSO for approximately 18 hours. 
RCC4 cells were lysed in EBC lysis buffer complemented with Set I and Set II 
phosphatase inhibitors at 1X (Calbiochem), and protease inhibitors at 1X (Roche). 
Whole cell lysate concentration was determined with Bio-Rad Protein Assay Dye 
Reagent Concentrate (Bio-Rad). Proteins were resolved on SDS–PAGE gels and 
electro transferred onto PVDF membranes (Millipore). Primary antibodies: c-Myc 
(1:1,000; SC-42), HIF1 (Cell Signaling #3716), HIF2 (Cell Signaling #7096), and b-actin 
(HRP) (Cell Signaling #5125).  
Cell culture conditions 
RCC4 cells were maintained and cultured in 1XDMEM, 10% FBS, 1% PS. 2 ug 
ml-1 of doxycycline was added to media to induce MYC expression overnight. In vitro 
doxycycline was dissolved in DMSO.  
RNA-seq analysis 
RNA was isolated and purified for RNAseq analysis using the RNeasy Mini Kit 
(Qiagen) following manufacturer’s protocol and eluted in water. A total of 200–1,000 ng 
of total RNA was used to prepare libraries with the TruSeq Stranded mRNA Sample 
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Prep Kit (Illumina). Around 75b paired-end reads were sequenced on a NextSeq 500 
Desktop Sequencer using a high output flow cell kit (Illumina), yielding an average of 
approximately 50 M reads per sample. QC-passed reads were aligned to the human 
reference genome using STARv2.5.3a. Transcript abundance estimates for each 
sample were performed using SALMONv0.9.1. Raw SALMON read counts for all 





*CHAPTER 3: MYC ACTIVATION COOPERATES WITH VHL AND INK4A/ARF LOSS 
TO INDUCE CLEAR CELL RENAL CELL CARCINOMA137  
 
Introduction 
Renal cell carcinoma (RCC) is among the most common malignancies, with an 
estimated 65,000 new cases and 14,000 deaths annually in the United States138. RCC 
can be subclassified into distinct histologic subtypes including clear cell RCC (ccRCC), 
papillary RCC Types 1 and 2, and chromophobe RCC139. Inherited RCC can be caused 
by germline mutations in multiple genes that are linked to specific histologic subtypes. In 
particular, VHL, MET, FH and FLCN genes are linked to development of the clear cell, 
papillary Type 1, papillary Type 2 and chromophobe RCC subtypes, respectively139–141. 
Not surprisingly, these genes are often found to be mutated in sporadic cases of RCC 
as well4,139–142. 
The genetics of ccRCC have been studied in depth141. The von Hippel-Lindau 
tumour suppressor protein (pVHL) is broadly inactivated (~80%) in sporadic ccRCC by 
either mutation or promoter hypermethylation140,143 and its tumour suppressor activity is 
dependent on its downregulation of the alpha subunits of the hypoxia-inducible factor 
(HIFa) family of transcription factors and in particular HIF2a124,125,144,145. In addition to 
                                            
* This chapter previously appeared as an article in the journal Nature Communications. The 
original citation is as follows: Bailey, S. T., Smith, A. M., Kim, W. Y. MYC activation cooperates 




mutations of VHL, whole exome sequencing studies have defined a number of other 
significantly mutated genes in ccRCC such as PBRM1, SETD2 and BAP1, many of 
which are related to histone modification or nucleosome remodeling4,5,75,141. ccRCC has 
a relatively low mutation burden relative to other solid tumours64 but does have 
characteristic large deletions and gains of chromosomes 3p, 14q and 5q, respectively, 
as well as more focal gains and losses of 8q24 (harbouring MYC) and 9p21 (harbouring 
CDKN2A), respectively4–6. 
Focal amplification of 8q24 has been demonstrated in ~15–23% of ccRCC in 
three independent studies and in all studies the amplicon appears to harbour MYC4–6 
Gain of 8q, as assessed by classic cytogenetics, is associated with a high risk of lymph 
node and distant metastases and is an independent prognostic factor113,146. Despite this 
genetic evidence implicating MYC in ccRCC pathogenesis, the role of MYC in ccRCC is 
complex. Studies demonstrate that HIF2a can potentiate MYC transcriptional activity 
and that MYC gene signatures are able to define a subtype of ccRCC, while HIF1a has 
the potential to oppose MYC transcriptional activity132,134,135. 
Herein we describe the development of mouse models of papillary and clear cell 
RCC, by modelling the genetic events found in human kidney cancer. We uncover that 
MYC activation is sufficient to generate papillary RCC in mice. Moreover, MYC 
activation, along with Ink4a/Arf (Cdkn2a) inactivation cooperates with Vhl loss to form 
clear cell RCC that is occasionally metastatic. These GEM models represent the first 
tractable models of papillary and clear cell RCC that have a predictable latency with 
high penetrance. These models of papillary and clear cell RCC should therefore be 
significant contributions to the field of kidney cancer research. 
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Kidney specific MYC activation results in papillary RCC 
 Prior work has examined the role of MYC in the development of kidney cancer by 
overexpressing MYC under control of the gamma-glutamyl transferase promoter147. While 
the mice developed renal tumours, they appeared to be histologically and 
immunophenotypically most consistent with collecting duct carcinomas. We generated 
compound mutant mice engineered to express a doxycycline-inducible Myc transgene 
(Tet-O-MYC) targeted to the renal tubule cells under control of the Ksp promoter8 (Ksp-
rtTA; Tet-O-MYC mice; hereafter called ‘MYC’ mice) and control animals expressing only 
Tet-O-MYC. Mice were fed chow containing doxycycline starting at ~8 weeks of age to 
induce MYC expression and were followed for survival. MYC mice had a significantly 
shortened survival relative to controls (Figure 3.1a, P= 0.0162) and upon necropsy were 

















Figure 3.1 Kidney specific MYC activation results in papillary renal cell carcinoma 
 
(a)Kaplan–Meier curve showing reduced survival rates in MYC mice (n ¼ 15) compared 
to controls (n ¼ 17) Log Rank P ¼ 0.0162. (b) Representative gross images and 
photomicrographs of H&E stained kidney sections from MYC mice (B32 weeks post Dox 
treatment) revealed both papillary (top panels) and solid kidney tumours (bottom panels) 
(scale bar, 100 mm). (c) GSEA enrichment plots showing papillary kidney tumours are 
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enriched for multiple gene sets representing MYC activation relative to normal kidney 
(GSE11151). (d) Kaplan–Meier curve of patients from the TCGA KIRP dataset 
demonstrating tumours with high MYC activity have reduced survival in patients with 
papillary renal cell carcinomas, Log Rank P ¼ 1.46e–9. (e) Immunoblot using whole cell 
lysates from MYC kidney tumor-derived cell lines (MYC-2927 and MYC-2983) shows 
expression of MYC is Dox dependent. (f) Cell viability assay show reduced proliferation 
from MYC-2927 and MYC-2983 cells upon Dox removal. Cells grown on Dox or vehicle 
were analyzed in replicates of n ¼ 8 each day. (g) Bright field image of MYC-2927 and 
MYC-2983 cells on day 3 after being cultured with or without Dox. (scale bar, 100 mm). 
(h) Soft agar assays show anchorage independent growth of MYC-2927 and MYC-2983 
cells is significantly reduced upon removal of Dox. Images are representative of each 
condition performed in triplicate. (i) Results from xenograft studies showing tumours 
formed from MYC-2983 cells remain dormant upon removal of Dox in vivo (n ¼ 5 per 
group). (f,g) *Po0.05, ***Po0.0001.(f,h,i) Data are presented  as mean ± s.e.m. (f,h) P 
values obtained from student  t-test. 
 
Histologic examination showed that the majority of the tumours found in the 
kidneys of MYC mice had either a papillary or a more solid and infiltrative appearance. 
Smaller tumours (<3 mm) were predominantly papillary (Figure 3.1b ‘papillary’), while 
larger tumours (>3 mm) were either papillary or consisted of more solid appearing 
tumours characterized by tightly packed papillary structures lacking distinct 
fibrovascular cores (Figure 3.1b ‘solid’). These larger, solid tumours were characterized 
by hyperchromatic cells with a high nuclear to cytoplasmic ratio. In addition, the cells 
contained nuclei with large nucleoli, significant pleomorphism and were high grade 
(Supplementary Figure 3.1A). Notably, intra-tumoral foamy macrophages and 
psammoma bodies (features that are commonly seen in human papillary renal cell 











Supplementary Figure 3.1 MYC activation in the kidney results in histological 
abnormalities 
 
(a) H&E staining of a representative kidney section from a MYC mouse reveals 
pleomorphism. (b) GSEA enrichment plots showing papillary tumors from TCGA KIRP 
are enriched for gene sets representing MYC activation relative to normal kidney. 
 
Papillary RCC with MYC activation has a worse prognosis 
 Prior work has shown that a subset of pRCC, primarily Type 2 pRCC, is enriched 
for gene signatures of MYC activation and that tumours with MYC activation have a 
worse overall survival.8 We confirmed and extended these findings using multiple gene 
expression datasets, which revealed that pRCC tumours were enriched for MYC 
activation gene signatures when compared to normal kidney (Figure 3.1c and 
Supplementary Figure 3.1b)148. Finally, to determine the impact of MYC activation on 
prognosis, we classified TCGA KIRP tumours as MYC activated (n=23, defined as 
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tumours with a Z score of the PID_MYC_ACTIV_PATHWAY greater than 1.0 s.d. above 
the mean) or not MYC activated (n=153). Consistent with previous work, patients with 
MYC activated pRCC tumours had a significantly worse overall survival (Figure 3.1d, 
p=1.46e-9)8. 
 
Cell lines from MYC mice are dependent upon MYC expression 
 To better characterize the phenotype of the kidney tumours from MYC mice we 
generated two cell lines from separate MYC tumours (MYC-2927 and MYC-2983). After 
verifying the Dox responsiveness of the Tet-O-Myc transgene in these MYC cells 
(Figure 3.1e), we examined the effect of MYC expression on cell proliferation in vitro. 
MYC cells grown in the presence of Dox (activated MYC) had increased proliferation at 
4 days (Figure 3.1f), as well as a visible increase in cell number (Figure 3.1g). In 
addition, while MYC cells with Dox were unable to form colonies in soft agar, MYC cells 
grown in Dox formed colonies robustly in an anchorage independent manner (Figure 
3.1h). Finally, we assessed the ability of MYC-2983 cells to form tumours in vivo and 
their in vivo growth dependence on MYC expression. To this end, 5x106 MYC-2983 
cells were injected subcutaneously and monitored for growth in mice fed Dox chow. 
Once tumours reached ~300mm3, mice were either continued on or withdrawn from Dox 
(Figure 3.1i). As expected, tumours of mice that remained on Dox continued to have 
rapid growth, while tumours in mice withdrawn from Dox remained dormant. Therefore, 




Vhl loss with MYC activation promotes clear cell changes 
Focal amplification of 8q24 is found in 15% of ccRCC in the TCGA KIRC data 
set4. To ensure that MYC was located in the minimal common region (MCR) of 
amplification, we used GISTIC 2.0 analysis to identify a broad statistically significant (q 
value<0.25) region of amplification on chr8. This MCR contains MYC. A plot of mean 
gene-level DNA copy number measurement by genomic position (Supplementary Data 
1 and Supplementary Figure 3.2a) shows that mean MYC copy number is larger than 
the 70% of the mean gene-level DNA copy values. Therefore, while these data suggest 
that MYC is an important target of amplification in this region there are still ~100 genes 
with mean copy number values that are higher. Similarly, focal loss of 9p21 was found 
in 32% of ccRCC in the TCGA KIRC data set4. GISTIC 2.0 analysis demonstrated the 
presence of only three genes in the minimal common region of copy number loss, 
CDKN2A, CDKN2B and C9orf53 (Supplementary Figure 3.2b). These results suggest 




















Supplementary Figure 3.2 GISTIC copy number by gene 
 
(a) GISTIC2 analysis on TCGA KIRC cohort of patients showing average DNA copy 
number measurements within region of amplification in chr8 for MYC and (b) region of 
deletion of chr9 for CDKN2A. 
 
To model the interplay of genomic events observed in human RCC, we next 
examined the phenotypes of kidney specific Vhl inactivation in combination with MYC 
overexpression or combined MYC overexpression and Ink/Arf deletion. Specifically, 
MYC mice were crossed to conditional Vhl knock-out mice (VhlF/F)54, Cdkn2a (Ink4a/Arf-
/-) germline knock-out mice149, as well as mice expressing tamoxifen-inducible Cre 
recombinase under control of the Ksp cadherin promoter (KspCreERT2) to generate 
cohorts of KspCreERT2; VhlF/F control mice (conditional inactivation of Vhl, hereafter 
called V), KspCreERT2; VhlF/F; Ksp-rtTA; Tet-O-Myc (conditional inactivation of Vhl and 
Dox-inducible MYC overexpression, hereafter called VM), and KspCreERT2; VhlF/F; 
Ink/Arf-/-; Ksp-rtTA; Tet-O-Myc (conditional inactivation of Vhl, germline Ink/Arf-/-, and 
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Dox inducible MYC overexpression, hereafter called VIM) (see Supplementary Table 
3.1). 
 
Supplementary Table 3.1 Summary of RCC GEM models 
 
 
Cohorts of V, VM, and VIM mice were followed for survival (Figure 3.2a). VM mice had 
a significantly worse survival than V mice (P=0.007) and VIM mice had a significantly 
worse survival than both V and VM mice (both P<0.001, Figure 3.2a). Histologic 
examination showed that the kidneys of V mice were essentially normal (Figure 3.2b). In 
contrast, kidneys from VM and VIM mice had a high incidence of tumour formation (67% 

















Figure 3.2 MYC activation combined with Vhl and Ink4a/Arf loss results in 
histopathological changes in the kidney resembling human clear cell renal carcinomas 
 
(a) Kaplan-Meier survival curve comparing survival rates between V (n.8), VM (n.21) 
and VIM (n.12) mice. Log rank V versus VM P.0.007, V versus VIM P<0.0001, VM 
versus VIM P<0.001. (b) Representative gross and H&E images of kidney sections from 
V (33 weeks), VM (30 weeks) and VIM (19 weeks) mice at the indicated times post Dox 
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treatment. (scale bars, 200 and 100 mm). (c) cBioPortal OncoPrint plot showing the 
distribution of MYC, VHL and CDKN2A copy number alterations in the TCGA KIRC data 
set. (d) Kaplan–Meier survival curve comparing human kidney renal clear cell 
carcinomas with V, VM and VIM alterations. Log rank V versus VIM P.5.08e-9, V versus 
VM P.0.005, VM versus VIM P.0.200. (e) Bar graph showing the correlation of V, VM 
and VIM tumours from the TCGA KIRC dataset with stage and (f) metastasis. (g) Bar 
graphs showing percentage of TCGA KIRC tumours with alterations in VHL, CDKN2A, 
and MYC by TNM Stage. (e–g) *P<0.05; **P<0.01, ***P<0.001. P values obtained from 
Chi-square test. 
 
Table 3.1 Comparison of VM and VIM mice 
 VM VIM 
Median survival (weeks after 
Tam/Dox) 
57 29.5 
Cysts present 9/9 (100%) 6/6 (100%) 
Kidney tumour present 6/9 (67%) 6/6 (100%) 
Large kidney tumour (>3mm) 2/9 (22%) 4/6 (67%) 
Low grade 3/9 (33%) 1/6 (17%) 
High grade 3/9 (33%) 5/6 (83%) 
Necrosis present 1/9 (11%) 4/6 (67%) 
Bona fide clear cell histology 0/9 (0%) 5/6 (83%) 
Liver metastases 0/9 (0%) 2/6 (33%) 
 
Kidney tumours of VM mice had either a tubulo-papillary or solid appearance with 
intervening vessels. The tumour cells were hyperchromatic compared to the normal 
renal tubular epithelium. Occasional clear cell features were identified (Figure 3.2b; 
Supplementary Figure 3.3). Small tumours were generally well demarcated, while larger 
tumours showed a multilobulated growth pattern with frequent necrosis, haemorrhage 














Supplementary Figure 3.3 Representative H&E images of VM and VIM mouse tumors 
 
Scale bar = 50um  
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Supplementary Figure 3.4 VM and VIM mice have histological abnormalities in their 
kidneys 
 
(a) H&E staining of a representative kidney section from a VM tumor. Arrows point to 
areas of hemorrhage and dystrophic calcifications. (b) PCR verification of Vhl deletion in 
the VM and VIM cell lines. (c) Heat map showing distinct expression patterns between 
3T3 fibroblasts and VM-3055 and VIM-3039 cell lines 
 
While tumours similar to those seen in the VM mice were observed in VIM mice, 
the kidneys of VIM mice also harboured tumours with a solid or tightly packed tubulo-
papillary appearance. The cells were small to intermediate in size with increased 
nuclear to cytoplasmic ratio with nuclei that were round to oval with prominent single 
nucleoli (Supplementary Figure 3.3). Clear cell changes within the larger tumours were 
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also present with areas within some tumours showing what appeared to be histology 
strikingly similar to human ccRCC (Figure 3.2b). These areas were typified by nests of 
tumour cells with an increased amount of clear to granular cytoplasm, separated by thin 
vascular channels. Therefore, while Vhl loss combined with MYC activation is sufficient 
to induce modest clear cell changes, Vhl loss combined with MYC activation and Ink/Arf 
deletion induces bona fide clear cell RCC (Table 3.1). 
ccRCC with VM and VIM alterations have worse prognosis 
 We next examined whether human ccRCC tumours with similar genomic 
characteristics (VHL inactivation; VHL inactivation and MYC activation; and VHL 
inactivation, CDKN2a loss and MYC activation) have similar outcomes as those seen in 
our mouse models. Of TCGA KIRC tumours (n=525), 87, 13, and 31% had VHL 
inactivation, MYC activation and CDKN2A deletion, respectively (Figure 3.2c). We 
further classified these patients as V (n=286, 54%), VM (n=26, 5%) and VIM (n=32, 
6.1%) and noted that VM and VIM patients had a significantly decreased survival 
relative to V patients (P=0.005 and P=5.086x10-9), respectively (Figure 3.2d), but that 
VM and VIM patients had a similar overall survival. In keeping with the notion that VIM 
tumours are more clinically aggressive, we also noted significant enrichment of higher 
stage and presence of metastases in patients with VIM tumours relative to patients with 
V tumours (Figure 3.2e,f). When limiting our analysis to stage IV tumours, we did not 
see significant survival differences by genotype (V, VM, and VIM) (Supplementary 
Figure 3.5). Because of the very limited patient numbers (V=28, VM=7, and VIM=11), 
we examined whether VIM genotype was prognostic when controlled for both TNM 
stage and Furhman grade. Cox proportional hazards (Cox PH) modelling using the V 
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genotype as the reference demonstrated that the VIM genotype was prognostic was still 
prognostic (Cox PH=1.79, P=0.034). Therefore, VIM tumours appear to have worse 
clinical characteristics and outcome in human ccRCC patients even when controlling for 
stage and grade. 
Supplementary Figure 3.5 No difference in survival among stage IV patients 
 
Kaplan-Meier survival curve of TCGA KIRC stage IV KIRC patients with V, VM, or VIM 
genotype. V (n=28), VM (n=7), VIM (n=11). Log rank V vs VM p=0.203, V vs VIM 
p=0.152, VM vs VIM p=0.995 
 
VM and VIM cell lines are dependent upon MYC expression 
We generated cell lines from VM and VIM tumours to assess their dependency 
on MYC expression. We first confirmed the Dox inducibility of the MYC transgene in 
these VM (2849 and 3055) and VIM (3039 and 3131) cells (Figure 3.3a), as well as the 
 52 
fact that they had undergone Cre mediated recombination of the Vhl locus 
(Supplementary Figure 3.4b). Furthermore, we set out to confirm that VM-3055 and 
VIM-3039 cell lines are epithelial in nature. We performed RNAseq and co-clustered 
mouse 3T3 fibroblasts with VM-3055 and VIM-3039 cell lines using the top 10% of the 
most differentially expressed genes (Supplementary Figure 3.4c). 3T3 fibroblasts show 
a distinctly different expression pattern from both VM-3055 and VIM-3039 cell lines 
showing that our VM and VIM cell lines are not fibroblastic in nature. After confirming 
that the VM and VIM cells were derived from renal epithelium, we assessed their growth 
in in vitro assays. Similar to MYC cells, the proliferation and anchorage independent 
growth of VM and VIM cells were dependent on MYC expression (Figure 3.3b–d). 
To understand the MYC dependent changes on the transcriptomes of VM-3055 
and VIM-3039 cells, we performed RNAseq on these cells grown in tissue culture in the 
presence or absence of Dox. There were a large number of genes that were 
differentially regulated (increased or decreased greater than two-fold; t-test FDR<0.05) 
by MYC activation (Dox) in both VM-3055 (799 up and 2491 down) and VIM-3039 (1017 
up and 2159 down) cells (Figure 3.3e). While there was overlap among genes that were 
upregulated by Dox in both VM-3055 (634 of 799) and VIM-3039 cells (634 of 1017) 
(Figure 3.3e), nearly a third of Dox inducible genes in VIM-3039 cells (378 of 1017) 
were not upregulated in VM-3055 cells. A similar percentage of genes repressed by 
MYC activation (Dox) in VIM-3039 cells were not repressed in VM-3055 cells either, 
suggesting that MYC may regulate both an overlapping and a unique spectrum of genes 




Figure 3.3 VM and VIM tumours are dependent on MYC expression 
 
(a) Immunoblot of whole cell lysates from VM (VM-2849 and VM-3055) and VIM (VIM-
3039 and VIM-3131) tumour-derived cell lines shows expression of MYC is Dox 
dependent. (b) Proliferation of VM and VIM cells is significantly reduced with removal of 
Dox. Cells grown on Dox or vehicle were analysed in replicates of n=8 each day. (c) 
Bright field image of VM and VIM cells three days after Dox removal show a decrease in 
cell number (scale bar, 100 mM). (d) Soft agar assays show anchorage independent 
growth of VM and VIM cells is reduced upon Dox removal. Images are representative of 
each condition performed in triplicate. (e) Venn diagram showing overlapping and 
distinct sets of genes altered upon Dox removal in VM-3055 and VIM-3039 cells. (f) 
Venn diagram showing Dox dependent gene expression in VM-3055 and VIM-3039 
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activates distinct gene sets. (b,d) ***P<0.0001. P values obtained from student t-test. 
Data are presented as mean ±s.e.m 
 
We next performed gene set analysis. Gene sets that were enriched in VM-3055 
cells cultured in Dox relative to those cultured without Dox included a number of gene 
signatures characteristic of MYC activation including those related to cell cycle 
progression and ribosome biogenesis (Supplementary Data 3.2). A parallel analysis in 
VIM-3039 cells also demonstrated high enrichment in proliferation and ribosome 
biogenesis gene signatures (Supplementary Data 3.3), but also included gene 
signatures related to DNA methylation, as well as RNA binding. Indeed, the top gene 
signatures significantly enriched in VM-3055 and VIM-3039 cells (an area under the 
curve (AUC) greater than 0.25) were relatively non-overlapping (Figure 3.3f). While 
these findings are in keeping with the notion that MYC activation induces many unique 
gene expression changes specific to VM-3055 and VIM-3039 cells given the analysis is 
on a single-cell line, they will need to be validated in future studies. 
 
GEM tumours correlate with human RCC 
Given that MYC tumours resemble human papillary tumours histologically, while 
VM and VIM tumours resemble ccRCC, we wanted to determine if the similarities would 
also be apparent at the gene expression level. Pearson correlations on whole 
transcriptome centroids between MYC (n¼4), VM (n¼4) and VIM (n¼4) mouse tumours 
and the TCGA KIRC and KIRP data revealed that VM and VIM tumours correlated most 
highly with TCGA KIRC tumours, while MYC tumours correlated more highly with TCGA 
KIRP tumours (Figure 3.4a). Further verifying the importance of MYC activity in pRCC 
Type 2, a cross species analysis of mouse MYC tumours with the TCGA KIRP data set 
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demonstrated co-clustering of MYC tumours with human papillary Type 2 tumours 
(Figure 3.4b). Moreover, transcriptome wide Pearson correlations revealed that MYC 
tumours more closely resemble TCGA KIRP tumours verified to be Type 2 pRCC 
(Figure 3.4c). Collectively, these analyses support the clinical relevance of the MYC, 
VM and VIM mouse models with human papillary and clear cell renal cancers. 
 
Figure 3.4 Renal carcinoma mouse models reflect the transcriptomic landscape of 
human renal carcinoma 
 
(a) Pearson correlation of whole-transcriptome centroids of M/VM/VIM mouse models 
and papillary renal cell carcinoma (KIRP)/clear cell renal cell carcinoma (KIRC) TCGA 
tumor samples. (b) Heatmap clustering of M mouse model samples with TCGA KIRP 
samples identified by subtype. (c) Pearson correlation of whole-transcriptome centroids 
of the M mouse model with KIRP TCGA Type 1/Type 2 samples. 
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Ink4a/Arf loss in VM mice promotes metastases 
During necropsies of VIM mice, we noted that a number of mice had what 
appeared to be macroscopic metastases to the liver at a low frequency (Figure 3.5a,b, 
and Table 3.1). Histologically, the liver metastases were either tubulo-solid or clear cell 
with cytologic features consistent with the primary renal tumour. Metastases were 
identified in the subcapsular area and within the parenchyma. Notably, vascular spaces 
were involved by tumour in some of the liver specimens (Figure 3.5a). We did not see 
any macroscopic metastases to other organs such as the lung. 
 Given the metastatic phenotype seen in the VIM mice but not in the VM mice, we 
examined a panel of genes that characterize epithelial to mesenchymal transition (EMT) 
(Cdh1 (E-cadherin), Cdh2 (N-cadherin), Vim (vimentin)), as well as a panel of 
transcription factors well known to regulate EMT (Snai1, Snai2, Zeb1, Zeb2, Twist1) in 
the RNAseq data from our cell lines. VIM-3039 cells demonstrated gene expression 
changes that were consistent with a state of EMT with decreased expression of E-
cadherin (Cdh1) and increased expression of N-cadherin (Cdh2) and Vimentin (Vim) as 
well as upregulated expression of Snai1, Snai2, Twist1, Zeb1 and Zeb2 (Figure 3.5c). In 
addition, we noted that a number of the most differentially expressed genes 
(Supplementary Data 3.4) are implicated in invasion and metastasis through remodeling 
of the extracellular matrix such as the lysyl oxidase family members Lox, Loxl1, Loxl2 
and hyaluronan synthase 2 (Has2)150–154. (Figure 3.5d). Given these differences in gene 
expression, we examined the invasiveness of our VM-3055 and VIM-3039 cell lines in 
vitro in matrigel invasion assays. As predicted, VIM-3039 cells had significantly 
increased matrigel invasion (Figure 3.5e). Therefore, Ink4a/Arf inactivation appears to 
 57 
facilitate EMT, invasion and metastases and the metastatic phenotype seen in vivo is 
recapitulated in vitro. 
Figure 3.5 Combinatorial loss of Vhl and Ink4a/Arf with MYC activation promotes 
metastasis and activation of EMT genes 
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(a) A representative H&E stained liver sections from a VIM mouse shows metastasis to 
the liver parenchyma as well as intravascular mets. Higher power magnification reveals 
features resembling renal clear cell carcinomas within the metastatic lesions. (Scale 
bar, 100 mm). (b) Bar graph showing percentage of mice with metastases. (c) Heat map 
showing the expression patterns of EMT associated genes in VM-3055 and VIM-3039 
cells. (d) Higher expression of genes involved in invasion and metastasis is observed in 
VIM-3039 cells compared to VM-3055 cells. (e) Matrigel invasion assays show 
increased invasion from VIM-3039 cells compared to VM-3055 cells. ****P<0.0001. (d,e) 
P values obtained from student t-test. Data are presented as mean ±s.e.m. 
 
 
VHL restoration has no effect on VIM cells 
Previous work in human ccRCC cell lines has shown that VHL does not affect in 
vitro proliferation or anchorage independent growth12. To assess whether this was true 
in our VIM cell lines, we established isogenic VIM cells expressing eGFP or HA-VHL 
(Figure 3.6a). As predicted, there were no VHL dependent differences in in vitro growth 
(Figure 3.6b) or ability to form colonies in soft agar (Figure 3.6c). These results are in 
keeping with those seen in human ccRCC cell lines. At this time, we have not been able 
to reliably generate allograft tumours from our VM or VIM cell lines and therefore cannot 
interrogate whether VHL plays a tumour suppressor role in vivo, as previously shown 
with human RCC cell lines12. Therefore, whether our GEM models are overdriven 




















Figure 3.6 Restoration of VHL does not significantly reverse tumorigenic capacity of VIM 
cells 
 
(a) Immunoblot of whole cell lysates from VIM cells infected with pBabe eGFP and 
pBabe HA-VHL. (b) Cell growth assay shows no significant reduction in cell number in 
VIM cells when VHL is expressed. Cells grown on Dox or vehicle were analyzed in 
triplicate each day. (c) Soft agar assays show VIM-3039 cells form colonies in an 
anchorage independent manner despite the presence of VHL. (b,c) P values obtained 




The development of GEM models of cancer has had significant impact on 
functional genomics as well as preclinical development of novel therapies. Indeed, 
robust GEMMs of non-small cell lung cancer155 and pancreatic ductal 
adenocarcinoma156 have led to an explosion of research into the biology underlying 
these diseases and facilitated the study of diverse fields such as biomarker discovery 
and investigations into the cell of origin of various cancers. Our own studies highlight 
the role of MYC in renal tumorigenesis and demonstrate that MYC activation is sufficient 
to generate papillary RCC and that when combined with Vhl and Ink4a/Arf inactivation 
results in bona fide clear cell renal cell carcinoma. 
 Development of robust GEM models of kidney cancer has been a long-sought 
after and elusive goal despite substantial efforts in this area. Multiple groups have now 
demonstrated that Vhl inactivation either in the germline or by conditional inactivation in 
the kidney results in only a mild increase in rate of renal cyst formation53–55,57,60. While 
the addition of secondary genetic events such as Pten or Kif3a loss appear to 
accelerate the cystic phenotype induced by Vhl inactivation, they do not result in frank 
neoplasia59,70. Combined inactivation of Vhl with Trp53 does appear to induce renal 
tumours, which have clear cell changes but not bona fide clear cell RCC histology66. A 
recent report demonstrated that combined inactivation of Vhl with Bap1 results in renal 
tumours with clear cell histology78. However, while inactivation of other tumour 
suppressor genes such as Flcn, Tsc1 or Fh results in renal carcinomas157–161, they are 
rarely of the clear cell histologic subtype and they exhibit long latency, impacting their 
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utility for routine investigation. Therefore, there remains a need for RCC models that are 
highly penetrant, relatively rapid and that display robust papillary or clear cell histology. 
 Schroff and colleagues recently reported the phenotype of kidney specific 
overexpression of c-MYC in mice147. They found robust development of renal tumours 
that were dependent on upregulated glutaminolysis. Histological and 
immunohistochemical analysis demonstrated that these tumours were most consistent 
with collecting duct carcinomas. Collecting duct carcinomas are thought to arise from 
the collecting ducts, which are embryologically derived from the metanephros and 
distinct from the nephron. In support of this, the immunophenotype, as well as response 
to therapy are closely associated with urothelial carcinomas (bladder cancer)162 and as 
such, they are treated with bladder cancer specific chemotherapy regimens such as 
MVAC (methotrexate, vinblastine, adriamycin, and cisplatin). Our studies also examined 
the phenotype of kidney specific overexpression of c-MYC. However, in contrast to 
Schroff and colleagues our MYC mice developed renal tumours with histology highly 
reminiscent of human papillary RCC. We hypothesize that these distinctions may be 
due to the relative differences in expression patterns of the promoters used to 
overexpress MYC (Schroff et al. use g-glutamyl transpeptidase while our studies use 
Ksp-cadherin), as well as any potential differences in the timing of MYC activation.  
 Our mouse models of pRCC and ccRCC faithfully recapitulate the genomics of 
human RCC although the incidence of ccRCC tumours that have coincident VHL and 
CDKN2A inactivation, along with MYC activation is only ~6%. The genomics of papillary 
and clear cell RCC implicate MYC as a potential oncogenic driver event4–6 and our 
studies firmly place MYC as playing an active role in their pathogenesis. VHL 
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inactivation results in the stabilization of the alpha subunits of the hypoxia-inducible 
factor alpha (HIF) family of transcription factors of which HIF2a is thought to be a key 
oncogenic driver of ccRCC tumorigenesis, while emerging evidence suggests that 
HIF1a may be a tumour suppressor gene124,127,140,144,145,163. Past work examining the 
potential interaction between HIFa subunits and MYC suggest that while HIF1a disrupts 
MYC transcriptional activity, particularly of those genes involved in cell cycle 
progression, HIF2a actually facilitates MYC/MAX interactions134,135,164. It will be 
interesting to determine whether these HIF and MYC interactions occur in vivo in our 
VM and VIM mouse models and whether these oncogenic dependencies can be used 
as therapeutic vulnerabilities. 
The Ink4a/Arf locus is best known as a cell autonomous barrier to cellular 
transformation through its negative regulation of cell cycle progression and its ability to 
promote cellular senescence165. Our studies demonstrate that Ink4a/Arf inactivation 
promotes liver metastases in an autochthonous ccRCC GEM model and that Ink4a/Arf 
loss is associated with gene expression patterns of EMT. Several past studies support 
that Ink4a/Arf may regulate EMT and metastasis. For example, in the mid 1990s, Allan 
Balmain and colleagues noted that p16 loss was a critical event in the regulation of an 
invasive spindle cell phenotype of mouse skin carcinomas, which today would likely be 
termed EMT166. In addition, a recent genome wide CRISPR screen in a cell line 
xenograft model identified CDKN2A as strongly associated with increased 
metastases167. At this time, we hypothesize that Ink4a/Arf loss does not directly regulate 
EMT or metastases but that its loss is permissive for the emergence of clones that allow 
metastatic behaviour. Nonetheless, our studies bolster the notion that Ink4a/Arf loss is a 
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metastatic driver event and demonstrate this association in autochthonous ccRCC GEM 
models. 
 In summary, we present GEM models of papillary and clear cell RCC that are 
faithful to the genomic events and recapitulate the histology seen in their respective 
human correlates. These pRCC and ccRCC GEM models should be a valuable 
contribution to the field of kidney cancer research and given their immune competent 




Conditional Vhl knock-out mice (VhlF/F)54, germline Cdkn2a (Ink4a/Arf) knockout 
mice (Ink4a/Arf-/-) 54 KspCad-CreERT2144, KspCad-rtTA168 and Tet-O-Myc mice have all 
been previously described. Tet-O-Myc was a generous gift from Dr Dean Felsher. 
Protocols for all animal experiments described were approved by the UNC-CH 
Institutional Animal Care and Use Committee. 
Reagents for in vivo studies 
 Conditional activation of cre recombinase was induced by oral administration of 
tamoxifen (Sigma T5648). Per ml of in vivo oral delivery, tamoxifen was formulated as: 
100 mg of tamoxifen dissolved in 100 ml 100% EtOH, followed by the addition of 1 ml of 
sunflower oil to achieve 100 mg ml-1. The solution was sonicated in a water bath 
sonicator located at 4°C for 10 second pulses. The solution was then placed in a water 
bath at 50°C for 1 minute until clear. Sonication and water bath steps were repeated 
until no particulates were noticeable. Animals were given 50 ul (5mg per day) for three 
consecutive days by oral gavage. Tamoxifen oral solution was aliquoted and stored at 
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20°C and brought to administrable solution by 50°C water bath for no longer than 5min. 
The Tet-ON conditional system was activated with doxycycline chow (Research Diets, 
Inc. C11300–2000 with 2,000 p.p.m. doxycycline) 7 days post oral 
tamoxifen administration. 
 
Primary tumour cell line generation and culture conditions  
 
Primary renal GEMM tumours were excised and washed in a solution of Pen-
Strep, PBS solution (1:1). In sterile conditions, primary tumours were cut into 2 x 2 mm 
fragments and dissociated in a gentleMACS C-Tube (Miltenyi Biotec) using the 
gentleMACs Dissociator (program: m_imp Tumor_02) in 5ml of 1XDMEM, 10% FBS, 
1% PenStrep. 100 ul of collagenase D/dispase II (Roche: 40 mg ml-1) was 
added to the tumour fragments and continuously inverted for 30 min at 37°C. Fragments 
were then subjected to a second round of dissociation using the gentleMACS 
Dissociator (program: m_imp Tumor_03). A total of 5 ml of protein extraction buffer 
(PEB: buffer 0.5% FBS, 2mM EDTA in PBS) was added to the dissociated fragments 
and resuspended by pipetting. The cell suspension was transferred to a 50 ml conical 
tube through a 40 mm nylon mesh sterile cell strainer (Fisher). An additional 20 ml of 
PEB buffer was added to the cell suspension and then centrifuged at 300g for 5 
minutes. Supernatant was removed and cell pellet was resuspended in 6ml of 
‘conditioned media’169 containing 2 ug ml-1 doxycycline (Sigma) and placed in a 6 cm 
sterile cell culture plate. On reaching confluency, cells were split and cultured in 
1XDMEM, 10% FBS, 1% PS containing 2 ug ml-1 doxycycline. In vitro doxycycline was 
dissolved in DMSO. 
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Xenograft 
 Primary renal GEMM tumour cell lines were implanted subcutaneously into SCID 
mice flanks at 5 x 106 cells in 200 ml of PBS containing 2 ug ml-1 doxycycline. To 
maintain expression of c-MYC, SCID mice harboring xenografts were placed on 
doxycycline chow and withdrawn from doxycycline at the indicated times. 
Immunoblotting conditions 
 Cells were lysed in RIPA buffer complemented with Set I and Set II phosphatase 
inhibitors at 1X (Calbiochem), and protease inhibitors at 1X (Roche). Whole cell lysate 
concentration was determined with Bio-Rad Protein Assay Dye Reagent Concentrate 
(Bio-Rad). Proteins were resolved on SDS–PAGE gels and electrotransferred to 
nitrocellulose membranes, 0.2 mm (Bio-Rad). For detection of c-MYC protein, proteins 
were electrotransferred onto PVDF membranes (Millipore). Primary antibodies, c-Myc 
(1:1,000; SC-42), VHL (1:500; SC-5575), Ku80 (1:1,000; Cell Signaling #2,180), 
Vinculin-HRP (1:1,000; Cell Signaling #18799); SC: Santa Cruz Inc. (Supplementary 
Figure 3.6). 
Cell viability assay 
Cell viability in the context of the various culture conditions was measured by 
CellTiter-Glo Luminescent Cell Viability Assay (Promega) per manufacture’s protocol. 
Cells were counted and in a 96 well opaque side/clear bottom cell culture plates 
(Corning). Luminescence measurements were captured using a Biotek Synergy 2 plate 
reader. Statistical significance was measured by student t-test. 
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Soft agar assay 
Anchorage independent growth was assayed following a standard soft agar 
assay protocol (bottom layer, 0.6% Difco Noble Agar (BD Biosciences) and top layer 
0.4% Noble agar (Difco)). 200 ml of control media or media containing 2 ug ml-1 
doxycycline was added to hydrate top agar every 72 hours. A total of 5,000 cells were 
plated in each well of a tissue culture treated 6 well plate (Corning). Colonies were 
stained with crystal violet solution for 4 h and destained with H2O. Pictures were taken 
using a digital camera (Cannon). Treatment conditions were performed in triplicate. 
Statistical significance was measured by t-test. 
Mouse RNAseq 
An equal number of cells (2 x 105 cells per dish) were plated with or without Dox 
and collected for RNA 24 h later. RNA was isolated and purified for RNAseq analysis 
using the RNeasy Mini Kit (Qiagen) following manufacturer’s protocol and eluted in 
water. A total of 200–1,000 ng of total RNA was used to prepare libraries with the 
TruSeq Stranded mRNA Sample Prep Kit (Illumina). Around 75b paired-end reads were 
sequenced on a NextSeq 500 Desktop Sequencer using a high output flow cell kit 
(Illumina), yielding an average of over 28 M reads per sample. QC-passed reads were 
aligned to the mouse reference genome (mm9) using MapSplice170. The alignment 
profile was determined by Picard Tools v1.64 (http://broadinstitute.github.io/picard/). 
Aligned reads were sorted and indexed using SAMtools and translated to transcriptome 
coordinates then filtered for indels, large inserts and zero mapping quality using UBU 
v1.0 (https://github.com/mozack/ubu). Transcript abundance estimates for each sample 
were performed using RSEM, an expectation-maximization algorithm (Li and Dewey, 
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2011) using the UCSC knownGene transcript and gene definitions171. Raw RSEM read 
counts for all RNAseq samples were normalized to the overall upper quartile172. 
Gene set analysis was performed between two groups of samples by first ranking 
all genes by t-statistic between groups. A K–S test was performed to determine if the 
genes in each gene set from MSigDB were uniformly distributed among the ranked list. 
K–S test P values were corrected via B–H procedure with an overall FDR of 5%. ROC 
curves were then generated for each gene set using the ranked list of t-statistics, and 
the AUC for the top 10% of ranked genes was used to rank gene sets among those 
passing the K–S test. 
Analysis of human renal gene expression data from TCGA 
 GSE11151 data set was downloaded on Jan 27, 2015 from Gene Expression 
Omnibus (GEO) website. RNA Expression dataset was log2-transformed/median 
centered across pRCC and normal tissue samples. RNA expression dataset was 
analyzed with the Gene Set Enrichment Analysis (GSEA) desktop platform. 
TCGA KIRP dataset was downloaded on Feb 1, 2015 from Broad TCGA website. 
RNA Expression dataset was log2-transformed/median centered. RNA expression data 
set was analyzed with the GSEA desktop platform. 
TCGA KIRC data sets were downloaded on Feb 15, 2015 from Broad TCGA 
website. RNA Expression dataset was log2-transformed/median centered. RNA 
expression dataset was analyzed with the cBioPortal Oncoprint function and on R 
platforms. 
 68 
Analysis of human copy number data from TCGA 
Gene-level segmented DNA copy values for the TCGA KIRC cohort (n.528) were 
downloaded from the Broad Institute GDAC (https://gdac.broadinstitute.org/). The 
GISTIC2 analysis (Mermel, 2012) identified a statistically significant (q<0.25) region of 
amplification in chr8 (69506698-146364022). Mean gene-level DNA copy number 
measurements were computed and plotted by genomic position. 
Correlation analyses 
The TCGA clear cell renal cell carcinoma (KIRC) and papillary renal cell 
carcinoma (KIRP) RNASeq expression datasets were downloaded through the Broad 
Institute pipeline (Broad Institute TCGA Genome Data Analysis Center (2016): 
Aggregate Analysis Features. Broad Institute of MIT and Harvard). Human homologues 
were identified for mouse genes from the Jackson Laboratory Mouse Genome 
Informatics database (http://www.informatics.jax.org/homology.shtml). When combining 
datasets, batch effects were adjusted for using the SVA (surrogate variable analysis) R 
package version 3.12.0. Centroids were derived by taking the median expression of 
each gene across samples in a designated sample cohort. Centroid similarity metrics 
were derived by calculating the Pearson correlation between centroids. Heatmap 
clustering was done using centered average linkage clustering on all expressed genes 
in the data set. 
Matrigel invasion assay 
RCC GEMM cell lines were plated in serum-free medium for 24 hours. A total of 
50,000 cells were seeded into an 8-mm matrigel chamber (BD Biosciences) and placed 
in wells containing medium containing 10% FBS. Cells were allowed to invade for 24 
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hours. Cells that had invaded through the matrigel were then stained with the Siemens 
Staining Kit according to manufacturer’s directions. Matrigel wells were then placed on a 
glass slide and analyzed and photographed using an Olympus IX51 microscope. 
Representative pictures were taken of each matrigel well quadrant, and the number of 
cells that had invaded into the matrigel was determined by counting the number of 
stained nuclei using ImageJ. 
Data availability 






CHAPTER 4: FINAL DISCUSSION 
 
Chapter 2 discussion and future directions 
As described above, we did not find any differentially expressed MYC dependent 
genes on a global scale to between H1H2 and H2 expressing cells. While this was 
surprising, work from Lin and colleagues demonstrated similar findings. They showed 
that MYC accumulates in the promoter regions of active genes across the genome and 
causes transcriptional amplification—but does not lead to newly activated or repressed 
MYC target genes. This was observed when authors compared two small cell lung 
carcinoma (SCLC) cell lines with either high (H2171 SCLC) or low (H128 SCLC) MYC 
expression. Gene expression analysis revealed that while H2171 cells had 
approximately 150-fold more c-MYC protein compared to H128, the set of transcribed 
genes were similar in low and high MYC expressing cell lines—indicating that elevated 
c-MYC levels do not significantly increase the number of expressed genes. 
While it is possible our results support this model, further analysis would need to 
be done to confirm this theory. It would be interesting to perform ChIP-seq for MYC on 
these cell lines to determine whether we would also observe increased MYC occupancy 
at core promoters and enhancers of active genes and whether there would be 
saturation at the high affinity E-box sites as well within our specific cell type. Would the 
localization of MYC at the promoters of active genes correlate to our gene expression 
data? ChIP-seq could also address whether our system of exogenous MYC induction is 
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at such high levels that MYC is overwhelming the ability of HIFs to exert their activity 
upon MYC activity.  
It would be quite valuable to generate an inducible system of MYC in which 
expression could be fine-tuned to not only control when it’s activated but how much is 
activated. This would allow us to investigate whether low levels of MYC induction would 
yield similar or completely different gene expression results. It would also be invaluable 
to perform such efforts in other pVHL deficient RCC cell lines. Understanding the 
molecular interplay between MYC and HIFs within ccRCC would serve a means of 
uncovering potential vulnerabilities for targeted therapies. 
 
Chapter 3 discussion and future directions 
 There is a vital need for GEM models that accurately recapitulate the molecular 
and histopathological features of human ccRCC. Significant work has been done over 
the years by several groups—including our own, to satisfy such a need. Our group has 
demonstrated that MYC overexpression within renal tubule cells gives rise to pRCC. 
Previous work from Shroff and colleagues also generated a mouse model that 
overexpressed MYC. However, their use of the gamma-glutamyl transferase promoter 
yielded tumors that were histologically consistent with collecting duct RCC (cdRCC)147. 
Such evidence strongly suggests that cell of origin may be just as crucial as genetic 
alterations in order to generate faithful models RCC.  
Large-scale genomic analysis revealed that focal amplification of 8q24 (MYC) is 
found in 15% of ccRCC tumors while ~32% undergo a focal loss of 9p21 (CDKN2A) . 
Such evidence led us to generate the following cohorts of mice all the presence of VHL 
loss. VM mice harbor a combination of VHL loss and overexpression of MYC within 
 72 
renal tubule cells and VIM mice harbor the combinatorial loss of VHL, germline deletion 
of Ink4a/Arf, and overexpression of MYC. We also generated a cohort of mice that only 
harbored inactivation of VHL, termed V mice. As expected, V mice had the greatest 
overall survival and did not develop tumors. However, VM and VIM mice experienced 
significantly worse overall survival, with VIM mice experiencing the worse overall 
survival out of all three cohorts. While VM mice did develop tumors at high penetrance 
of 67%, VIM mice had a 100% penetrance, were generally of a higher grade, displayed 
clear cell histology, and displayed some instances of liver metastases (~33%). It should 
be noted that while VIM tumors recapitulated some of the most characteristic features of 
ccRCC, there were some interesting observations within this model.  
Metastases was only observed within the VIM cohort; albeit at a relatively low 
rate (Table 3.1). A previous study by Bianchi and colleagues assessed the distribution 
of various sites of metastases in patients with RCC and found the most common site to 
be the lung (45%)173. This was followed by bone (30%), lymph node (22%), and liver 
(20%) as the next most frequent sites of metastases among RCC patients. It should be 
noted that there was no sub-classification of the primary tumors other than cancer of 
kidney—so one cannot ascribe the frequency of metastases being attributable to a 
specific subtype of RCC. Nonetheless, while we did not see any metastases to the lung, 
it is possible that our model still represents a subset of RCC patients that do experience 
liver metastases.  
Additionally, the upregulation of genes involved in promoting invasion and 
metastases through remodeling of the extracellular matrix (ECM) in VIM cell lines 
supports the metastatic phenotype observed in this model (Figure 3.5d). However, one 
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should note that such analysis was performed in one representative VIM cell line. It 
would be worth determining whether such findings would be supported in VIM primary 
tumors by looking at the gene expression data of the same genes. I would hypothesize 
that we would find similar results seeing as that tumors provide a more reliable depiction 
of the microenvironment compared to cell lines that are grown on plastic. Furthermore, 
is it possible that the aggressive nature of the VIM tumors were not specific to the 
inactivation of Ink4a/Arf in the kidney—but due to the systemic loss of Ink4a/Arf? It 
would be interesting to determine whether deletion of Ink4a/Arf within the kidney would 
yield the same aggressive phenotype. As such, GEM models are indispensable tools to 
better understand and investigate the complexities of disease. Our GEM models of 
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